Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Serum homocysteine increases after therapy with fenofibrate or bezafibrate.

Literature DB >> 10421307

Serum homocysteine increases after therapy with fenofibrate or bezafibrate.

Abstract

A 44% and 17.5% increase of homocysteine occurred in patients treated either with fenofibrate or bezafibrate. The increase was not explained by changes in vitamin concentrations but may be related to renal function.

Entities: Chemical Species

Mesh：

Substances：

Year: 1999 PMID： 10421307 DOI： 10.1016/S0140-6736(99)02153-4

Source DB: PubMed Journal: Lancet ISSN： 0140-6736 Impact factor: 79.321

Keyword Cloud
Cited

22 in total

Review 1. Fibrates for treatment of the metabolic syndrome.

Authors: Kevin C Maki
Journal: Curr Atheroscler Rep Date: 2004-01 Impact factor: 5.113

Review 2. Fenofibrate: a review of its use in primary dyslipidaemia, the metabolic syndrome and type 2 diabetes mellitus.

Authors: Gillian M Keating; Katherine F Croom
Journal: Drugs Date: 2007 Impact factor: 9.546

Review 3. Consensus statement on management of dyslipidemia in Indian subjects.

Authors: K Sarat Chandra; Manish Bansal; Tiny Nair; S S Iyengar; Rajeev Gupta; Subhash C Manchanda; P P Mohanan; V Dayasagar Rao; C N Manjunath; J P S Sawhney; Nakul Sinha; A K Pancholia; Sundeep Mishra; Ravi R Kasliwal; Saumitra Kumar; Unni Krishnan; Sanjay Kalra; Anoop Misra; Usha Shrivastava; Seema Gulati
Journal: Indian Heart J Date: 2014-12-24

10. Beneficial effects of danshensu, an active component of Salvia miltiorrhiza, on homocysteine metabolism via the trans-sulphuration pathway in rats.

Authors: Yg Cao; J G Chai; Y C Chen; J Zhao; J Zhou; J P Shao; C Ma; X D Liu; X Q Liu
Journal: Br J Pharmacol Date: 2009-04-30 Impact factor: 8.739

Serum homocysteine increases after therapy with fenofibrate or bezafibrate.

Review 1. Fibrates for treatment of the metabolic syndrome.

Review 2. Fenofibrate: a review of its use in primary dyslipidaemia, the metabolic syndrome and type 2 diabetes mellitus.

Review 3. Consensus statement on management of dyslipidemia in Indian subjects.

Review 4. Fenofibrate: a review of its use in dyslipidaemia.

5. Cystathionine beta synthase gene dose dependent vascular remodeling in murine model of hyperhomocysteinemia.

Review 6. Managing dyslipidemia in chronic kidney disease.

7. Fenofibrate-induced hyperhomocysteinemia may be prevented by folate co-administration.

8. Synergism in hyperhomocysteinemia and diabetes: role of PPAR gamma and tempol.

Review 9. The association of homocysteine and coronary artery disease.

10. Beneficial effects of danshensu, an active component of Salvia miltiorrhiza, on homocysteine metabolism via the trans-sulphuration pathway in rats.